BMS Celebrates A New Day in Cancer Treatment with Approval of Opdualag

Every week, BioSpace reports on incremental advances in cancer treatment, and while they might seem like just that to the average eye, they mean a great deal to those patients. But on Friday, Bristol Myers Squibb achieved a monumental milestone when the U.S. Food and Drug Administration approved Opdualag (nivolumab and relatlimab-rmbw) for the treatment of patients 12 and older with unresectable or metastatic melanoma.